Literature DB >> 17041099

The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.

Shrikanta Chattopadhyay1, Rongbao Zhao, Eugenia Tsai, Vern L Schramm, I David Goldman.   

Abstract

Pemetrexed is a new-generation antifolate inhibitor of thymidylate synthase (TS) and a weaker inhibitor of glycinamide ribonucleotide transformylase (GARFT) required for de novo purine synthesis. Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma. The current study addresses the effect of MTAP on pemetrexed activity using a highly potent transition state inhibitor of MTAP, MT-DADMe-Immucillin A (ImmA; K(i) = 86 pmol/L) in the MTAP(+) NCI-H28 and MTAP(-) NCI-H2052 mesothelioma cell lines. Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations. ImmA had no effect on pemetrexed activity but, when thymidine was added, the pemetrexed IC(50) decreased by a factor of approximately 3 in MTAP(+) H28 cells with no effect in MTAP(-) H2052 cells. Conversely, the transfection of MTAP into H2052 cells increased the pemetrexed IC(50) by nearly 3-fold but only in the presence of thymidine; this was reversed by ImmA. An MTAP-specific short interfering RNA produced a 2-fold decrease in pemetrexed IC(50) in MTAP(+) HeLa cells in the presence of thymidine. These data indicate that suppression of constitutive MTAP has no effect on pemetrexed activity when the primary target is TS. There is a modest salutary effect when the pemetrexed target is GARFT alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17041099     DOI: 10.1158/1535-7163.MCT-06-0313

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  6 in total

1.  Design and synthesis of potent "sulfur-free" transition state analogue inhibitors of 5'-methylthioadenosine nucleosidase and 5'-methylthioadenosine phosphorylase.

Authors:  Alistair I Longshaw; Florian Adanitsch; Jemy A Gutierrez; Gary B Evans; Peter C Tyler; Vern L Schramm
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

Review 2.  Treatment of acute lymphoblastic leukaemia : a new era.

Authors:  Effrosyni Apostolidou; Ronan Swords; Yesid Alvarado; Francis J Giles
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.

Authors:  Sally A Coulthard; Christopher P F Redfern; Svante Vikingsson; Malin Lindqvist-Appell; Karin Skoglund; Ingrid Jakobsen-Falk; Andrew G Hall; Gordon A Taylor; Linda A Hogarth
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

4.  The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

Authors:  J E Nutt; A R A Razak; K O'Toole; F Black; A E Quinn; A H Calvert; E R Plummer; J Lunec
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

5.  Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed.

Authors:  Steven F Powell; Arkadiusz Z Dudek
Journal:  Pharmgenomics Pers Med       Date:  2009-06-24

6.  Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma.

Authors:  Jihao Xu; Wen-Hsin Chang; Lon Wolf R Fong; Robert H Weiss; Sung-Liang Yu; Ching-Hsien Chen
Journal:  Signal Transduct Target Ther       Date:  2019-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.